Mon.Jan 13, 2025

article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

Health data company Truveta said Monday it’s partnering with health systems and drugmakers to launch the Truveta Genome Project , a database of genetic data that is expected to accelerate personalized medicine and help discover new drugs.  Truveta plans to use leftover biospecimens from patients — after they consent — receiving routine health care at participating health systems to create the database.

article thumbnail

Patient death after pharmacy unable to supply epilepsy medication sparks call for action

The Pharmacist

A community pharmacy and the sector's regulator have been told to take action following the death of a man who was unable to obtain his epilepsy medication. David Crompton, aged 44, died following a fall on 13 December 2024, made more likely by the absence of medication, the coroner suggested. In December 2024, the pharmacy […] The post Patient death after pharmacy unable to supply epilepsy medication sparks call for action appeared first on The Pharmacist.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: J&J to buy Intra-Cellular Therapies for $14.6B, picking up mental health drug

STAT

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will provide a boost as the industry gathers for one of its largest events of the year. With the acquisition, the pharma giant will get Intra-Cellular’s Caplyta, which is approved to treat schizophrenia and bipolar-related depression.

article thumbnail

AI is set to improve R&D productivity and lower costs

Express Pharma

Artificial intelligence (AI) has the potential to significantly reduce pharmaceutical R&D costs by streamlining drug discovery, optimising clinical trials, and minimising costly failures through data-driven predictions and effectiveness assessments. This potential was acknowledged by the pharmaceutical industry professionals in a survey* conducted by GlobalData.

article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

STAT+: Cigna, Centene, Walgreens drop out of J.P. Morgan conference

STAT

SAN FRANCISCO — Cigna and Centene have bowed out of this year’s J.P. Morgan Healthcare Conference, a possible sign that leaders of large health care companies are looking to avoid public appearances in light of the assassination of a high-profile executive last month. The health insurance giants are among 11 major companies that dropped out of the industry’s main investor event, according to the final agenda posted by J.P.

358
358

More Trending

article thumbnail

STAT+: GSK to buy cancer-focused IDRx in $1 billion deal

STAT

LONDON — Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront. The deal, which includes another $150 million in milestone payments, gives GSK an experimental treatment for a rare gastrointestinal cancer.  The announcement comes as much of the biopharma world gathers in San Francisco for the J.P.

article thumbnail

Global Alzheimer’s disease market to reach $19.3 bn in 8MM by 2033

Express Pharma

The global Alzheimers disease (AD) market across the eight major markets (8MM*) is forecast to grow from $2.4 billion in 2023 to $19.3 billion by 2033 at a compound annual growth rate (CAGR) of 23.4 per cent, primarily driven by the entry of expensive disease-modifying therapies (DMTs) into the market, which will likely result in increased treatment rates as more options become available, an aging global population leading to an increase in prevalent cases, and the launch of novel symptomatic th

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations.

article thumbnail

Lupin launches Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) in the US

Express Pharma

Lupin announced the launch of Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets), 0.1 mg/0.02 mg and 36.5 mg in the United States, after having received approval from the United States Food and Drug Administration (US FDA). Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) 0.1 mg/0.02 mg and 36.5 mg is a generic equivalent of Balcoltra (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate T

105
105
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA ‘stuck to its corner’ with AI draft guidance, leaving plenty of questions unanswered

PharmaVoice

The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.

article thumbnail

AI set to revolutionise pharmaceutical R&D says GlobalData

Pharma Times

Survey finds AI to enhance productivity and cut costs in the next 12 months

144
144
article thumbnail

The ability to pivot will be ‘key’ as pharma’s tariff threat looms

PharmaVoice

Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.

147
147
article thumbnail

Gilead and LEO Pharma partner to develop oral STAT6 program

Pharma Times

Companies aim to provide new treatments for inflammatory conditions

141
141
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

GSK acquisition to advance potential best-in-class GI tumour treatment

European Pharmaceutical Review

GSK has agreed to acquire the biopharmaceutical firm IDRx Inc, a company focused on development of precision therapies for gastrointestinal stromal tumours (GIST). The deal is valued up to $1.15 billion, which includes an upfront payment of $1 billion. IDRx Inc could receive a further $150 million, subject to achievement of future regulatory approvals.

59
article thumbnail

Moderna shares tumble on slashed sales guidance

BioPharma Dive

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

Vaccines 122
article thumbnail

JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic

Pharmaceutical Technology

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

article thumbnail

GSK confirms plan to buy cancer firm IDRx for $1bn

pharmaphorum

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

103
103
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

The 43rd Annual J.P. Morgan Healthcare Conference Starts Today – A Who’s Who in Biologics at this Year’s Conference

Big Molecule Watch

J.P Morgan states that the JP Morgan Healthcare Conference (JPM) is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. On January 15, 2025, Goodwin and KPMG will host their 6th Annual Symposium.

article thumbnail

J&J to buy psychiatric drug developer Intra-Cellular for $14.6B

BioPharma Dive

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

article thumbnail

Nine-month-old obesity player Metsera files an IPO

pharmaphorum

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

98
article thumbnail

Drug Channels Leadership Forum: Request an Invitation Before It’s Too Late!

Drug Channels

The inaugural Drug Channels Leadership Forum (DCLF) is coming soon! This exclusive event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Our first event will provide attendees with an opportunity to explore the most pressing strategic issues and crucial uncertainties that will impact all participants across U.S. drug channels.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Regeneron, Illumina join $320m Truveta investment

pharmaphorum

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

95
article thumbnail

Three drug cocktail shows potential to boost CAR-T cancer therapy

World Pharma News

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen receptor-T cells) to fight cancer. This finding may have a significant impact on improving the production of CAR-T cells for clinical use.

article thumbnail

How data science and AI will transform life sciences in 2025

pharmaphorum

Discover how data science and AI are set to revolutionise the life sciences industry by 2025, with a focus on mRNA technology and CRISPR gene editing. Stay ahead of the curve with these cutting-edge advancements.

82
article thumbnail

Lilly pads cancer drug pipeline with Scorpion deal

BioPharma Dive

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.

70
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.